Gastroenterology
Latest news
416 articles · 20 / page
Lean MASLD Is Not Benign: Higher Liver Events and Mortality in Normal-BMI Patients Across Three Large Cohorts
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 bloc
GWAS of Idiopathic Achalasia Reveals a Strong HLA Class II–Mediated Immune Aetiology and T-Cell Involvement
A first large GWAS in 4,602 idiopathic achalasia patients implicates class II HLA variation, PTPN22, TNFSF loci and a memory CD8+ T-cell subtype in disease pathogenesis, supporting an immune-mediated aetiology and offering routes for mechan
HBsAg <100 IU/mL Identifies Inactive Chronic HBV Patients with HCC Risk Below Surveillance Threshold
A large Asian cohort study shows serum HBsAg
Peginterferon Add‑On to siRNA JNJ‑73763989 Yields Deep HBsAg Declines but Not Durable Off‑Therapy Cure in HBeAg‑Positive CHB: Phase 2 REEF‑IT Results
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
Not All ‘Indeterminate’ HBV Is Equal: Specific Indeterminate Types Carry Markedly Higher Long‑Term HCC Risk
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
Seladelpar Significantly Reduces Itch and Sleep Disturbance in PBC: Pooled Phase 3 Evidence and Clinical Implications
Pooled analysis of the ENHANCE and RESPONSE phase 3 trials shows seladelpar 10 mg reduces pruritus and sleep disturbance in patients with primary biliary cholangitis (PBC) and moderate-to-severe baseline itch versus placebo over 6 months, w
Immune-related adverse events strongly predict early graft rejection after liver transplant in HCC patients treated with checkpoint inhibitors
A multicentre retrospective cohort found that pretransplant immune-related adverse events (irAEs) markedly increase the risk of early liver allograft rejection after liver transplantation for hepatocellular carcinoma (HCC). IrAEs, short ICI
Understanding Nonceliac Gluten/Wheat Sensitivity: A Global Perspective on a Common But Complex Condition
Nonceliac gluten/wheat sensitivity affects about 1 in 10 people worldwide, with strong links to female sex, psychological distress, and irritable bowel syndrome. This article explores its prevalence, symptoms, challenges in diagnosis, and i
FDA Approves Linzess for Pediatric IBS with Constipation: A New Hope for Children
The FDA has approved linaclotide (Linzess) for treating irritable bowel syndrome with constipation (IBS-C) in children 7 and older, marking the first official treatment option for pediatric IBS-C.
Therapeutic Plasma Exchange May Improve Transplant-Free Survival in Severe Amatoxin-Associated Acute Liver Failure
A multinational retrospective cohort found adjunctive plasma exchange was associated with higher 28‑day transplant-free survival in amatoxin-related ALF patients with grade ≥2 hepatic encephalopathy.
Predicting Early Acute Kidney Injury After Liver Transplantation: A Clinically Useful 48‑Hour Risk Model
A single-center study developed and internally validated a 48‑hour post‑liver transplant AKI risk model using five readily available preoperative and intraoperative variables (HE, alcohol cirrhosis, ALBI ≥ −1.78, operation time ≥560 min, an
Exceptional Efficacy of Olverembatinib in a Subtype of Gastrointestinal Stromal Tumors with Marked Improvement in Progression-Free Survival
Olverembatinib showed outstanding efficacy in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), significantly extending median progression-free survival to 25.7 months compared to traditional therapies
Higher Early IV Fluid Rates Tied to More SIRS but Lower BUN Rise in Acute Pancreatitis: Findings From an International Cohort Presented at ACG 2025
An international prospective cohort found that higher early IV fluid rates were associated with lower odds of BUN rise but higher odds of new or persistent SIRS at 6 and 24 hours after presentation, highlighting confounding issues and the n
Recent Advances in Alcohol Metabolism: from the Gut to the Brain
This article reviews the latest findings on human alcohol metabolism, covering evolutionary biology, systemic and brain-specific pathways, genetic and physiological modulators, clinical implications of metabolic variability, and emerging th
Gastrointestinal Burden in CHARGE Syndrome: High Prevalence of Constipation, Age-Related Patterns, and Quality‑of‑Life Impact
In a cohort of 50 individuals with CHARGE syndrome, GI problems affected 64% and constipation 48%, with constipation associated with lower PedsQL GI scores and greater comorbidity; younger patients had more diverse GI issues while older pat
Expanding Donor Pools: Outcomes of Liver Transplantation Using Grafts from Medical Assistance in Dying Donors in Canada
This Canadian multicenter study evaluates liver transplant outcomes using grafts from donation after medical assistance in dying donors, showing comparable survival and complication rates to standard donors and increasing transplant activit
Advances in Gastrointestinal Cancer Therapeutics: Insights from NICHE-2, FOxTROT, Telisotuzumab Adizutecan, and Emerging Trials
This article reviews pivotal updates in gastrointestinal oncology from recent trials, emphasizing superior neoadjuvant immunotherapy in mismatch repair–deficient colorectal cancer, promising antibody-drug conjugates, and challenges in novel
Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice
This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibr
Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial
The phase II ELMWOOD trial demonstrates that elafibranor, a dual PPAR-α/δ agonist, is well tolerated and significantly improves biochemical markers in patients with primary sclerosing cholangitis over 12 weeks, warranting further investigat
Browse by specialty
Open language-specific specialty feeds and department pages.